Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;13(6):430-5.
doi: 10.1007/s11906-011-0229-4.

Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated Cardiotoxicity

Affiliations
Review

Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated Cardiotoxicity

Rajesh Gupta et al. Curr Hypertens Rep. .

Abstract

Kinase inhibitors have emerged as an important new class of agents for the treatment of diverse tumors. Sunitinib malate is a small-molecule, oral, multi-kinase inhibitor approved for use in treating renal cell carcinoma and gastrointestinal stromal tumor. It has also demonstrated efficacy in treating pancreatic neuroendocrine tumors and is being evaluated for the treatment of other cancers. Initially developed for its inhibition of the vascular endothelial growth factor (VEGF) signaling pathway, sunitinib has been associated with hypertension and heart failure. This review examines the incidence and severity of these adverse events, relevant findings from other agents that inhibit VEGF signaling, the mechanisms underlying these effects, and suggestions for their clinical management. Hypertension is a common adverse effect that is usually easily managed. The associated heart failure is less common; it can be reversible but must be actively monitored and managed. Mechanistic insights suggest that an attentive clinical strategy for hypertension could prevent severe cardiotoxicity.

Similar articles

See all similar articles

Cited by 10 articles

See all "Cited by" articles

References

    1. N Engl J Med. 2011 Feb 10;364(6):501-13 - PubMed
    1. J Clin Oncol. 2011 Feb 20;29(6):632-8 - PubMed
    1. Lancet. 2007 Dec 15;370(9604):2011-9 - PubMed
    1. N Engl J Med. 2007 Jan 11;356(2):115-24 - PubMed
    1. J Clin Oncol. 2007 Sep 20;25(27):4278-84 - PubMed

MeSH terms

LinkOut - more resources

Feedback